PAMS

Leading PRM, Partner Marketing & Sales Ecosystem Enablement Solution Provider, Mindmatrix, Enhances its Sales Playbooks Module with Next-gen Sales Automation capabilities

Retrieved on: 
Wednesday, April 10, 2024
PAMS, Ecosystem, Risk, Distortion, Partnership, Workflow, Automation, PRM, Marketing, Knowledge, Sales

PITTSBURGH, April 10, 2024 /PRNewswire-PRWeb/ -- Next-generation PRM, partner marketing and sales ecosystem enablement solutions provider, Mindmatrix Inc., has unveiled its enhanced Sales Playbooks Module that revolutionizes sales automation for not just direct sales, but also across the partnership and channel ecosystem. This upgrade represents a significant advancement in sales automation, offering businesses streamlined sales workflows, improved user experiences, and superior efficiency in their sales processes.

Key Points: 
  • PITTSBURGH, April 10, 2024 /PRNewswire-PRWeb/ -- Next-generation PRM , partner marketing and sales ecosystem enablement solutions provider, Mindmatrix Inc. , has unveiled its enhanced Sales Playbooks Module that revolutionizes sales automation for not just direct sales, but also across the partnership and channel ecosystem.
  • The revamped Sales Playbooks module introduces several key features aimed at empowering direct and indirect sales teams and channel partners thereby optimizing their performance.
  • It features advanced sales automation capabilities, enabling sales representatives to streamline their processes and focus on high-value activities.
  • Experience the power of the enhanced Sales Playbooks module and transform your sales processes with Mindmatrix Inc.

Taste Modulators Market Analysis by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical) - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Technology, Retail, Food Tech, Food, Beverage, Health, Module (mathematics), Tate & Lyle, Government, Taste, Growth, Market development, Row, DSM, Research, Increase, Investment, Snack, PAMS, USD, Medicine, Hypertension, Extensive, Renewable energy

The "Global Taste Modulators Market by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical), and Region (North America, Europe, Asia-Pacific, South America, RoW) - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Taste Modulators Market by Type (Sweet Modulators, Salt Modulators, Fat Modulators), Application (Food, Beverages, Pharmaceutical), and Region (North America, Europe, Asia-Pacific, South America, RoW) - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The adaptability of salt modulators across diverse food applications, ranging from snacks to processed foods, further solidifies their market dominance.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the Taste Modulators market.
  • The report also helps stakeholders understand the Taste Modulators market and provides them with information on key market drivers, restraints, challenges, and opportunities.

AI Can Speed Design of Health Software

Retrieved on: 
Wednesday, March 6, 2024
Software design, Engineering, MCIT, Internet, Research, Doctor of Philosophy, Medicine, Population health, Artificial intelligence, Multimedia, Health, Digestive, Language, Exercise, Learning, ChatGPT, Synthetic media, NYU, Kidney, Nursing, NYU Langone Health, Patient, Journal, Intuition, Physician, PAMS, Software, Medical device

NEW YORK, March 6, 2024 /PRNewswire/ --Publishing online March 6 in the Journal of Medical Internet Research, the study examined the capabilities of a form of artificial intelligence (AI) called generative AI or GenAI, which predicts likely options for the next word in any sentence based on how billions of people used words in context on the internet. A side effect of this next-word prediction is that the generative AI "chatbots" like chatGPT can generate replies to questions in realistic language, and produce clear summaries of complex texts.

Key Points: 
  • Led by researchers at NYU Langone Health, the current paper explores the application of ChatGPT to the design of a software program that uses text messages to counter diabetes by encouraging patients to eat healthier and get exercise.
  • The team tested whether AI-enabled interchanges between doctors and software engineers could hasten the development of such a personalized automatic messaging system ( PAMS ).
  • If this proves to be effective at scale it could revolutionize healthcare software design."
  • AI could take software design only so far before human software developers were needed for final code generation, but the overall process was greatly accelerated, say the authors.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024
MSD, Schizophrenia, BNC210, Deficit spending, Patient, Module (mathematics), PAMS, PTSD, Post-traumatic stress disorder, Sleep, Partnership, Merck & Co., GAD, NAM, Anxiety, Neuropsychiatry, SAD, Alzheimer's disease, Central nervous system, Australian Securities Exchange, FDA, DSM-IV codes, CIAS, Breakthrough therapy, Panic, Merck, Phase, Data analysis, Data, CNS, Social anxiety disorder, Pharmaceutical industry

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
Wednesday, January 3, 2024
Biology, Entrepreneurship, Partnership, ALS, Gene editing, Cardiology, A101, Drug development, R100, Protein engineering, FDA, CRISPR, Cystic fibrosis, Disease, Tissue, Brain, PAMS, Vivisection, AAV, Artificial intelligence, DSM-IV codes, Ophthalmology, CNS, Engineering, Machine learning, Genome, Central nervous system, Patient, Therapy, Vaccine

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Retrieved on: 
Wednesday, January 3, 2024
Biology, Entrepreneurship, Partnership, ALS, Gene editing, Cardiology, A101, Drug development, R100, Protein engineering, FDA, CRISPR, Cystic fibrosis, Disease, Tissue, Brain, PAMS, Vivisection, AAV, Artificial intelligence, DSM-IV codes, Ophthalmology, CNS, Engineering, Machine learning, Genome, Central nervous system, Patient, Therapy, Vaccine

Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.

Key Points: 
  • Arbor also has expertise in CNS biology, CNS drug development and CNS therapeutic development.
  • 4DMT has utilized its platform to invent customized AAV vectors for CNS tissues, and these vectors will be deployed in the partnership.
  • “CNS disorders include some of the most devastating diseases, many of which have a genetic origin.
  • We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines.

Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors

Retrieved on: 
Tuesday, December 12, 2023
NYSE, DNA, Gene editing, Protein engineering, Genome, Ginkgo Bioworks, CRISPR, PAMS, Ginkgo, Patient, Codebase, Foundry, Vaccine, Pharmaceutical industry, Arbor

Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases.

Key Points: 
  • Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases.
  • "Ginkgo's expertise aligns well with our goals, and their technology will synergize with our in-house capabilities, potentially fueling a faster, more efficient expansion of our toolbox of gene editing technologies."
  • "This collaboration with Arbor is an exciting project for us, as it gives us an opportunity to leverage our platform-driven approach to contribute to the gene editing sector's fast-moving evolution.
  • We look forward to expanding our capabilities in this field by working with such an innovative pioneer as Arbor to power technologies with the potential for transformative impact."

Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability

Retrieved on: 
Thursday, October 26, 2023
Science, AAV, DCAS, Facioscapulohumeral muscular dystrophy, Biotechnology, FSHD, PAMS, Congress, Dicarboxylic acid, Cell, GEMS, Gene, ESGCT, European Society of Gene and Cell Therapy, Patient, Gene expression, SAN, Vaccine, Cas

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.

Key Points: 
  • These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.
  • Among the data being presented are new details on Epic’s in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas protein known to work in human cells.
  • In new data at ESGCT, Epic reports that these three Cas effectors also display greater flexibility in the genetic sequences, called PAMs, that they can target.
  • “These data highlight why GEMS is an unparalleled therapeutic platform, and how our team’s unique expertise is expanding the state of the science in epigenetic editing every day.”

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Retrieved on: 
Thursday, September 14, 2023
MSD, GABAA receptor positive allosteric modulator, Ion channel, Human, Society, Central nervous system, PAM, Royal Society of Chemistry, Pharmacokinetics, Research, RSC, Society of Chemical Industry, Patient, Chemical industry, DSM-IV codes, Acetylcholine, Merck, Merck & Co., SCI, PAMS, BioScience Research Collaborative, Pharmaceutical industry, Bionomics

MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.

Key Points: 
  • MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.
  • Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products.
  • This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone.
  • Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Retrieved on: 
Monday, July 24, 2023
Epilepsy, Scripps Research, Nicotine, PAM, ADX71149, Oxycodone, LR, Research, Opioid, Trial of the century, Discovery, Glutamic acid, Cocaine, Motivation, Drug, Rat, SCM, PAMS, SIX, SD, Biology, Pharmaceutical industry, Neuropharmacology

The data were published in Neuropharmacology by Addex and The Scripps Research Institute.

Key Points: 
  • The data were published in Neuropharmacology by Addex and The Scripps Research Institute.
  • “In the United States, opioid abuse and overdose have reached epidemic proportions, with oxycodone being the most abused prescription opioid.
  • In previous research, this approach has successfully been used in nicotine, cocaine and alcohol models,” said Dr. Robert Lütjens, Head of Discovery – Biology at Addex.
  • “Demonstrating the wide potential of mGlu2 PAMs, an Addex discovered drug candidate, ADX71149, is being evaluated in a phase 2 clinical study as a potential treatment for epilepsy by our partner Janssen.”